Latest Developments
03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.
MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety
01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product
MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.
Engaged in the Development
and marketing of novel immun theraputic applications of a Natural Gamma-Interferon (nG-IFN)
Our Vision is to Establish a Biotechnology company by developing novel immune therapeutic applications of natural gamma-interferon therapy to treat cancer and infectious diseases.
What is an Interferon?
Interferon (IFN) is a type of protein called a cytokine that is secreted by cells of the body during an infection. It can inhibit viruses from spreading to neighboring cells and it can aid in destroying cancerous cells. Interferon therapy takes advantage of these natural protective properties. Commercial interferon is used as a treatment for viral infections, such as hepatitis C, and as a treatment for certain cancers. Learn more »
What Does A5 Do?
A5 Laboratories provides contract analytical, regulatory and product development services to the Pharmaceutical industry. With a dedicated commitment to its client’s needs, A5 Laboratories offers a full range of services to the pharmaceutical industry in variety of fields, all in compliance with Good Laboratory Practices and current Good Manufacturing Practices regulations.